Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.

Respiratory research·2024

Same author

Association between lung function and dyspnoea and its variation in the multinational Burden of Obstructive Lung Disease (BOLD) study.

Pulmonology·2024

Same author

Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET.

Respiratory research·2024

Same author

Atrial fibrillation and survival on a medical intensive care unit.

International journal of cardiology·2023

Same author

[Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (ÖGP), the Austrian Society for Infectious and Tropical Diseases (ÖGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)].

Pneumologie (Stuttgart, Germany)·2021

Same author

Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade.

Infection·2021

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Community-acquired pneumonia].

¹Abteilung Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625, Hannover, Deutschland. welte.tobias@mh-hannover.de

|January 22, 2009

Summary

This summary is machine-generated.

Community-acquired pneumonia (CAP) is a leading infectious cause of death globally. Risk stratification guides antibiotic choice and treatment setting, while vaccinations significantly reduce CAP incidence and severity.

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Related Experiment Videos

Last Updated: Jun 26, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Experimental Model to Evaluate Resolution of Pneumonia

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Area of Science:

Infectious Diseases
Public Health
Internal Medicine

Context:

Community-acquired pneumonia (CAP) represents the most common fatal infectious disease worldwide.
Hospitalized patients face significantly higher mortality rates (approx. 14% in Germany) compared to outpatients (<1%).
Elderly individuals in nursing homes and patients with comorbidities are particularly vulnerable.

Purpose:

To outline the current risk stratification approach for initiating antibiotic therapy in CAP.
To emphasize the importance of appropriate initial antibiotic selection based on patient risk.
To highlight the role of influenza and pneumococcal vaccinations in CAP prevention.

Summary:

CAP management hinges on risk stratification to determine outpatient vs. inpatient treatment and antibiotic spectrum.
Low-risk CAP patients benefit from narrow-spectrum beta-lactams for 5 days.
High-risk patients necessitate hospital admission and broader-spectrum antibiotics covering atypical pathogens.

Impact:

Effective CAP management strategies, including risk stratification and vaccination, can significantly reduce mortality and disease burden.
Implementation of Ständige Impfkommission (Stiko) vaccination recommendations is crucial for public health in Germany.
Optimizing antibiotic therapy based on risk assessment is key to improving patient outcomes in CAP.